Wang Lixuan, Jiang Weibo, Yang Manshi, Danzeng Quezhu, Liu Shiyu, Cui Mengying
Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, 130000, China.
Orthopedic Medical Center, The Second Hospital of Jilin University, China, Jilin, 130000, Changchun.
Cell Commun Signal. 2025 Jun 5;23(1):270. doi: 10.1186/s12964-025-02275-z.
Over the past decade, there has been a qualitative improvement in the understanding of gut microbiota in cancer development and treatment. Gut microbiota regulates metabolic reprogramming that occurs in the competition between tumor cells and immune cells for essential nutrients in the tumor microenvironment (TME). Besides, gut microbiota dysbiosis is one of the key factors leading to the formation of aging environment, which has many similarities with the TME. Accumulating research findings have demonstrated that gut microbiota enhances the efficacy of cancer therapies by activating the immune system and facilitating the biotransformation of drugs. Other studies also have shown that specific microbial composition is the effective biomarker of drug resistance and toxicity for cancer treatment. Microbiota-directed therapies are being explored intensively for their potential in cancer prevention and treatment. In this review, we summarize the role of gut microbiota in metabolic reprogramming and immune remodeling; provide an overview of the relationship between gut microbiota and the efficacy, resistance, and toxicity of cancer treatment; propose a series of strategies to integrate gut microbiota into cancer treatment, optimizing antitumor effectiveness and reducing side effects.
在过去十年中,人们对肠道微生物群在癌症发展和治疗中的理解有了质的提升。肠道微生物群调节代谢重编程,这种重编程发生在肿瘤微环境(TME)中肿瘤细胞与免疫细胞争夺必需营养物质的竞争过程中。此外,肠道微生物群失调是导致衰老环境形成的关键因素之一,而衰老环境与TME有许多相似之处。越来越多的研究结果表明,肠道微生物群通过激活免疫系统和促进药物的生物转化来提高癌症治疗的疗效。其他研究还表明,特定的微生物组成是癌症治疗中耐药性和毒性的有效生物标志物。针对微生物群的疗法因其在癌症预防和治疗中的潜力而正在被深入探索。在这篇综述中,我们总结了肠道微生物群在代谢重编程和免疫重塑中的作用;概述了肠道微生物群与癌症治疗的疗效、耐药性和毒性之间的关系;提出了一系列将肠道微生物群纳入癌症治疗的策略,以优化抗肿瘤效果并减少副作用。